Relapse With Rituximab More Common in Severe Pemphigus Relapse With Rituximab More Common in Severe Pemphigus

Pemphigus patients with severe disease and those with persistent anti-desmoglein (DSG) antibodies three months after starting treatment with rituximab are more prone to relapse while on the drug, according to a new post hoc analysis of a randomized clinical trial.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news